Research and Development Investment: Amgen Inc. vs Viatris Inc.

A Decade of Innovation: Amgen Inc. vs Viatris Inc.

In the ever-evolving pharmaceutical industry, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, Amgen Inc. and Viatris Inc. have demonstrated contrasting strategies in their R&D expenditures. From 2014 to 2023, Amgen consistently invested significantly more in R&D, with an average annual expenditure of approximately $4.2 billion. This commitment underscores Amgen's focus on pioneering new treatments and maintaining its competitive edge.

In contrast, Viatris Inc., formed in 2020 through the merger of Mylan and Upjohn, has averaged around $735 million annually in R&D. Despite its smaller scale, Viatris has shown a steady increase in R&D spending, peaking in 2023 with a 58% rise from its 2020 levels. This growth reflects Viatris's strategic shift towards innovation and expansion in the global pharmaceutical market.

These investment patterns highlight the diverse approaches of two industry giants in navigating the challenges and opportunities of the pharmaceutical landscape.